Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Operating Expenses (2023 - 2025)

Historic Operating Expenses for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Q3 2025 value amounting to $45.7 million.

  • Monte Rosa Therapeutics' Operating Expenses rose 2797.75% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $173.0 million, marking a year-over-year increase of 2019.6%. This contributed to the annual value of $156.7 million for FY2024, which is 936.63% up from last year.
  • Monte Rosa Therapeutics' Operating Expenses amounted to $45.7 million in Q3 2025, which was up 2797.75% from $38.7 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' 5-year Operating Expenses high stood at $47.6 million for Q4 2024, and its period low was $34.3 million during Q1 2023.
  • For the 3-year period, Monte Rosa Therapeutics' Operating Expenses averaged around $38.7 million, with its median value being $37.2 million (2023).
  • Over the last 5 years, Monte Rosa Therapeutics' Operating Expenses had its largest YoY gain of 3665.78% in 2024, and its largest YoY loss of 331.37% in 2024.
  • Quarter analysis of 3 years shows Monte Rosa Therapeutics' Operating Expenses stood at $34.9 million in 2023, then surged by 36.66% to $47.6 million in 2024, then dropped by 3.99% to $45.7 million in 2025.
  • Its last three reported values are $45.7 million in Q3 2025, $38.7 million for Q2 2025, and $40.9 million during Q1 2025.